Zoeken
Algemene medische oncologie

Klinische studies hoofd- en hals tumoren

Op deze pagina

Planned

There are currently no planned studies in our center.

Ongoing

MCLA-158-CL02

A phase III open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma.

MCLA-158-CL03

A phase III randomized, open label study to evaluate the efficacy and safety of Petosemtamab plus Pembrolizumab vs. Pembrolizumab in head and neck squamous cell carcinoma in the first line treatment of PD-L1+ (CPS≥1) metastatic/recurrent disease without curative therapy available.

Closed

AIM-HN & SEQ-HN KO-TIP-007

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

ASPEN-03 AT148003

A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamos Cell Carcinoma

CDI-CS-002

An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma

DUTRELASCO ESR-16-12192

Durvalumab plus Tremelimumab in resectable, locally advanced squamous cell carcinoma of the head and neck: a window of opportunity study

EAGLE D4193C00002

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

ELEVATE - GS-US-548-5916

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

EORTC 1206

A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing, salivary gland cancer (SGCs)

INDUCE-4

A Randomized, Double-Blind, Phase III Study of GSK3359609 in Combination with Pembrolizumab and Platinum-based Chemotherapy versus Placebo in combination with Pembrolizumab plus Platinum-based Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

INTERLINK-I

Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor.

KEYNOTE-412 MK-3475-412

A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma

LUZERA-301 ASP-1929-301

Phase 3 Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Standard of Care for Locoregional Recurrent Head/Neck Squamous Cell Carcinoma in Patients Who Have Failed After at Least Two Lines of Therapy

OPCEMISA ISA101b-HN-01-17

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)

UPSTREAM EORTC-1559-HNCG

A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

WAVE D910FC00001

An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols

Laatste aanpassing: 28 maart 2025